(Ebook) Innovate, Fund, Thrive: The Entrepreneur's Playbook to VC Fundraising in Life Sciences by Jean-François Denault, Philippe Tramoy

(Ebook) Innovate, Fund, Thrive: The Entrepreneur's Playbook to VC Fundraising in Life Sciences by Jean-François Denault, Philippe Tramoy

Entrepreneurs in life sciences face a unique set of challenges when raising funds in life sciences. These start with more traditional concerns such as managing R&D risk, building a viable commercialization model to more specific challenges such as articulating your message and managing your investor relationships. The life sciences industry consists of companies operating in the fields of pharmaceuticals, biotechnology, medical devices, and biomedical technologies and all have unique requirements to succeed which require a solid financial foundation and funding. The authors present this book in two parts. In the first part, the focus is on getting ready to meet potential partners and investors and include topics such as identifying the information organizations and start-ups need, collecting and collating as well as building a compelling story. The second part will be focused on preparing the ‘pitch’ to secure funding whether internally or externally and include topics such as “Five mistakes that sink a presentation each time”, an insight on how investors review and evaluate proposals as well as a behind the scenes look at the due diligence journey. While the book is split in two parts, it is written in an integrated fashion, with both authors commenting based on their individual strengths while sharing feedback and perspectives in relevant sections. For example, Tramoy gives us an insider view into the diligence process from an investor’s point of view, and Denault shares his perspective and insights on how a company can prepare their pitch to address some of the key points that might otherwise derail an investment evaluation. The book also includes practice advice, including feedback and comments from successful entrepreneurs, venture capitalist and Big Pharma.